New Jersey law requires prescribers and pharmacists to review a patient’s prescription history prior to prescribing and dispensing highly addictive opioid pain medications and other CDS that, when used in conjunction with opioids, can place patients at a higher risk of fatal overdoses. ![]() "It is yet another tool as we work to end addiction and save lives." “We're using the latest technology to fight the opioid crisis, and that includes our new NarxCare platform," said Attorney General Grewal. The recently launched “NarxCare” platform is the latest NJ PMP enhancement paid for with funds from the $100 million that the Murphy Administration committed to combatting the opioid epidemic in FY2019. New Jersey prescribers and pharmacists can now track patients’ use of controlled dangerous substances (“CDS”) on a new NJ PMP platform that automatically examines the data on file, analyzes it, and generates an interactive, patient-centered report with visual enhancements – including patient risk alerts – to ensure that patients are not being overprescribed opioid pain medications that can lead to addiction, overdose, and death. ![]() Grewal, the Division of Consumer Affairs, and the New Jersey Coordinator for Addiction Responses and Enforcement Strategies ("NJ CARES") today announced enhancements to the NJ Prescription Monitoring Program (“NJ PMP”) that make it easier for prescribers and pharmacists to identify and manage patients at risk for controlled substance abuse and misuse.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |